Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Satellite Symposia webcasts

ESMO Congress 2021 - 1000x1000

Watch the webcasts from our industry partners Satellite Symposia

17/09/2021

Servier - The clinical value of mIDH1 inhibition in cholangiocarcinoma

Watch session

  • Isocitric dehydrogenase: an actionable genetic alteration in cholangiocarcinoma
    Arndt Vogel
  • The scientific rationale for mIDH1 inhibition
    Juan Valle
  • Clinical evaluation of mIDH1 inhibition
  • Discussion on the clinical value of mIDH inhibition
    Arndt Vogel, Angela Lamarca
  • Identifying patients with mIDH1: how and when to do molecular testing
  • What does all this mean for a patient with cholangiocarcinoma
    Arndt Vogel, Angela Lamarca
  • Q&A + Discussion
    Arndt Vogel, Angela Lamarca, Juan Valle

AstraZeneca - From Breast Cancer Biology to Therapy

Watch session

  • Welcome and Introductions
    Ian Krop
  • Overview of targetable biomarkers in breast cancer
    Thomas Bachelot
  • The evolution of targeted therapies shaping the future of breast cancer care
    Komal Jhaveri
  • Panel Discussion and case studies
    Ian Krop, Thomas Bachelot, Komal Jhaveri
  • Summary and close
    Ian Krop

AstraZeneca - Re-evaluating the role of gBRCA in breast cancer

Watch session

  • Welcome and introduction
    Sibylle Loibl
  • What do we know about gBRCAm breast cancer?
  • gBRCAm eBC - Emerging evidence and management strategies and implications for clinical practice and patient outcomes
    Andrew Tutt
  • When to test for gBRCA?
    Christian Singer
  • Case-based panel discussion
    Sibylle Loibl, Aleix Prat, Andrew Tutt
  • Closing remarks
    Sibylle Loibl
  • Live Q&A
    Sibylle Loibl, Aleix Prat, Andrew Tutt

Medscape - A Stepwise  Approach To Managing HR+/HER2- Early Breast Cancer: From Risk Assessment To Risk Management

Watch session

  • Introduction
    Joyce O'Shaughnessy
  • First step: identify patients at high risk of recurrence
    Joyce O'Shaughnessy
  • Second step: managing a patient at high risk of recurrence
  • Third step: monitoring and counseling patients
    Valentina Guarneri
  • How would you manage this patient with HR-positive/HER2-negative EBC? A Live Test and Teach Session
    Joyce O'Shaughnessy, Valentina Guarneri
  • Concluding remarks
    Joyce O'Shaughnessy

Bayer - Taking action in nmCRPC: Cases in the clinic

Watch session

  • Welcome and introduction
    Bertrand Tombal, Alicia Morgans
  • Living with nmCRPC: A patient’s perspective
    Mark Hein, Alicia Morgans
  • Meeting patient needs: Understanding nmCRPC treatment options
    Bertrand Tombal
  • Case 1: Treat early for extended survival
  • Case 1: Live discussion
    Alicia Morgans
  • Case 2: Maintain current lifestyle and keep active
  • Case 2: Live discussion
    Bertrand Tombal
  • Case 3: Minimise drug-drug interactions with other co-medications
    Alicia Morgans
  • Case 3: Live discussion
    Bertrand Tombal, Alicia Morgans
  • Summary
    Alicia Morgans
  • Live Q&A
    Bertrand Tombal, Alicia Morgans

18/09/2021

Pfizer Oncology - Expert Perspectives in ALK+NSCLC: a round table discussion

Watch session

  • Welcome and introduction
    Nicolas Girard
  • Recent advances in ALK+ NSCLC
    Ben Solomon
  • Treatment selection and sequencing: decision making in 2021
  • The importance of managing CNS disease
    Nicolas Girard
  • Optimising patient outcomes: treatment management options
  • Q+A session
    Nicolas Girard
  • Wrap up and close
    Nicolas Girard

Pfizer Oncology - Confidence and clarity in advanced breast cancer: Insights from the real world

Watch session

  • Welcome & introduction
    Véronique Diéras
  • Moving forward in the treatment of endocrine-sensitive HR+/HER2– aBC
    Debra Patt
  • Building confidence in the treatment of challenging populations in endocrine-resistant HR+/HER2– aBC
    Rebecca Dent
  • Increasing clarity in diagnosing and treating germline BRCA-mutated aBC
    Fernando Petracci
  • Q&A and discussion
    "Veronique Dieras, Rebecca Dent, Fernando Petracci,
    Debra Patt"

Pfizer Oncology - Complex Management of Relapsed and Refractory Multiple Myeloma (RRMM) and Evaluation of Unmet Needs

Watch session

  • Introduction
    Xavier Leleu
  • Evaluating Treatment Strategies in RRMM and Unmet Needs
    Nizar Bahlis
  • Discussing Clinical Practice: Relapsed vs Refractory MM
    Xavier Leleu
  • Exploring Novel Targets in RRMM
    Maria Mateos Gonzalez
  • Q&A (Live)
    Nizar Bahlis, Xavier Leleu, Maria Mateos Gonzalez
  • Conclusions (Live)
    Xavier Leleu

Janssen - Expanding horizons for the targeted management of EGFR+ NSCLC

Watch session

  • Welcome and introductions
    David Planchard, Keith Kerr
  • Disease progression in patients with common EGFR mutations
    Johan Vansteenkiste, David Planchard, Keith Kerr
  • Precision diagnostic and therapeutic approaches for EGFR exon 20 insertions
    Alexander Spira, David Planchard, Keith Kerr
  • Key learnings and closing remarks
    David Planchard, Keith Kerr
  • Live Q&A
    David Planchard, Keith Kerr, Alexander Spira, Johan Vansteenkiste

19/09/2021

Janssen - A Decade’s Perspective on Advances in Prostate Cancer

Watch session

  • Welcome and introduction
    Amit Bahl, Laura-Maria Krabbe
  • Advanced prostate cancer: Lessons learned from the last decade
  • Optimising the management of patients with advanced prostate cancer: Key questions in 2021
    Amit Bahl, Laura-Maria Krabbe, Elena Castro, Steven Joniau
  • Vision for the future
  • Live Q&A
    Amit Bahl, Laura-Maria Krabbe, Steven Joniau, Elena Castro
  • Close of meeting
    Amit Bahl, Laura-Maria Krabbe

Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: how will they impact our daily practice?

Watch session

  • Welcome and Introductions
    Andrea Necchi
  • Recurrence Post-Radical Resection: Are Systemic Therapies the Solution to Optimize Patient Outcomes?
    Andrea Necchi
  • Biomarkers: Are We Ready to Use Them in Routine Clinical Practice?
    Matthew Galsky
  • QoL: Is It a Key Endpoint in the Adjuvant Setting?
    Matthew Galsky
  • Clinical Cases Discussion (Cisplatin-eligible case; Cisplatin-ineligible case)
    Andrea Necchi, James Catto, Matthew Galsky
  • Closing Remarks
    Andrea Necchi
  • Live Q&A session
    Andrea Necchi, James Catto

AstraZeneca - Redefining long-term outcomes in newly diagnosed advanced ovarian cancer: Expert perspectives on integrating personalized medicine

Watch session

  • Key considerations for treatment of newly diagnosed advanced ovarian cancer
    Nicoletta Colombo
  • Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD positive: BRCA 1/2 mutation
    Ana Oaknin
  • Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD Positive: no BRCA mutation, high genomic instability score
    Christian Marth
  • Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD Negative: Low genomic instability score
    David O'Malley
  • Future Perspectives
    Nicoletta Colombo
  • Panel Discussion and Q&A
    Nicoletta Colombo, Christian Marth, Ana Oaknin, David O'Malley

Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations

Watch session

  • Welcome and Introduction
    Martin Reck
  • Is a one size fits all approach still appropriate for NSCLS with an EGFR mutation, are all mutations equal?
    Joachim Aerts
  • Scientific rationale for dual inhibition of VEGF and EGFR
    Nobuyuki Takakura
  • Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us?
    Federico Cappuzzo
  • Case study from the clinic – Potential patient profile and include sequencing and discuss with panel
  • Panel discussion and Q&A
    Martin Reck, Joachim Aerts, Federico Cappuzzo
  • Symposium closing remarks
    Martin Reck

AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease

Watch session

  • Introduction
  • Shifting towards cure: How to optimise early stage patient identification. EGFR-reflex testing and non smoking related LCs screening in the light of new data in adjuvant setting
  • Panel discussion: what outcomes should we expect in early stage NSCLC: the importance of targeting the right patients with the right treatment
    Helena A. Yu
  • Real world evidence: How 3rd gen TKIs have shaped clinical practice in 1L metastatic EGFRm NSCLC
    Helena A. Yu
  • Panel discussion: Learnings from RWE in 1L metastatic EGFRm NSCLC
    Helena A. Yu
  • Closing remarks

GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors

Watch session

  • Welcome and introduction
    Thierry André
  • Biomarkers for treatment with immune checkpoint inhibitors. Where are we now?
    Josef Rüschoff
  • Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced/recurrent endometrial cancer
  • Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H solid tumors
    Thierry André
  • Patient case report panel discussion: Biomarkers in pan tumor treatment
    Thierry André, Josef Rüschoff
  • Live Q&A
    Thierry André, Josef Rüschoff

Astellas - The evolving landscape of advanced prostate cancer

Watch session

  • Welcome and Introduction
    Heather Payne
  • Making a difference to patients' lives in metastatic hormone-sensitive prostate cancer (mHSPC): where we are now?
    Antonio Alcaraz
  • When to treat metastatic hormone-sensitive prostate cancer (mHSPC)
    Arnulf Stenzl
  • The patient with metastatic hormone-sensitive prostate cancer (mHSPC)
    Heather Payne
  • Panel Discussion and Conclusion
    Antonio Alcaraz, Heather Payne, Arnulf Stenzl

Boehringer Ingelheim - CTRL + ALT + DEL: Disrupting Cancer’s Operating Functions

Watch session

  • Welcome and Introduction to Topics and Speakers
  • Controlling cancer cell hallmarks to deliver breakthrough therapies
  • Altering outcomes for rare tumors with new treatment options
    Mrinal Gounder
  • Rebooting checkpoint inhibition with smart combinations
    Hossein Borghaei
  • Deleting tumors through novel approaches to ramp up the immune system
    Ulrich Lauer
  • Closing and Key Takeaways

20/09/2021

Bristol Myers Squibb - From Rational to Daily Practice: Navigating Through 1L IO-based Treatment Options in Advanced RCC

Watch session

  • State of the Art 1L Therapy in aRCC
    Laurence Albiges
  • Should Cure Be A Reasonable Goal in aRCC? Expert to Expert Case Discussions
  • Q&A and Closing Remarks
    Laurence Albiges

Ipsen - Spotlight on emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Watch session

  • Welcome and introduction
    Peter Galle
  • Where are we now? Evolving our strategy in 1L RCC
    Manuela Schmidinger
  • Where are we now? Optimising treatment beyond first line
    Daniel Heng
  • Sequencing in HCC: Choosing the right direction with our patients
    Peter Galle
  • Evolving the landscape: New data for the future of RAI-R DTC treatment
    Jaume Capdevila
  • Thank you and close
    Peter Galle
  • Q&A
    Peter Galle, Jaume Capdevila, Manuela Schmidinger, Daniel Heng

Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers

Watch session

  • Welcome and Introductions
    Luis Paz-Ares
  • The Evolving Role of I-O in Thoracic Cancers
    Luis Paz-Ares
  • Is I-O Changing Survival Expectations in mNSCLC?
    Luis Paz-Ares
  • Is I-O in Resectable NSCLC a Reality?
    Tina Cascone
  • Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?
  • Panel Discussion
    Luis Paz-Ares, Tina Cascone
  • Live Q&A and Closing
    Luis Paz-Ares, Tina Cascone

21/09/2021

Bristol Myers Squibb - Shaping tomorrow today: What does the future hold for melanoma?

Watch session

  • Welcome and Introduction
    Caroline Robert
  • Direction: opportunities to improve patient outcomes
    Caroline Robert
  • Development: exploring treatment targets and combinations
  • Delivery: optimizing patient management
  • Dialogue: Live discussion and Q&A
    Caroline Robert, Georgina Long

Servier - Extend the continuum of care and improve patient outcomes in mGC and mCRC

Watch session

  • Introduction
    Thierry André
  • Extend continuum of care in mGC
    Sylvie Lorenzen
  • Improve treatment efficacy and patient outcomes in 3L mCRC
    Harpreet Wasan
  • Future landscape for non-intensive 1L mCRC treatment
    Elena Elez
  • Conclusion
    Alberto Sobrero
  • Q&A
    Alberto Sobrero, Thierry André, Sylvie Lorenzen, Harpreet Wasan, Elena Elez

AstraZeneca - Emerging Agents in Breast Cancer Care

Watch session

  • Welcome and Opening
    David Miles
  • Next Evolutions – HER2+
    Mark Pegram
  • Next Evolutions – TNBC
    Seock-Ah Im
  • Next Evolutions – HR+
    Erika Hamilton
  • Panel Discussion and Q&A
    David Miles, Mark Pegram, Erika Hamilton, Seock-Ah Im

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Watch session

  • Introduction to PARPi maintenance therapy
    Alexandra Leary
  • Individualized patient care during PARPi maintenance therapy
  • Bringing the evidence together: efficacy, safety, and quality of life
  • Discussion 
    Alexandra Leary

Bristol Myers Squibb - Immuno-oncology for GI cancers: A clinical lens on current data

Watch session

  • Welcome and Introduction
    Eric Van Cutsem
  • I-O treatment for colorectal cancers: Where do we stand?
    Eric Van Cutsem
  • I-O therapies for gastric cancers: Advancing into earlier treatment settings
    Yelena Janjigian
  • The evolving treatment landscape for esophageal cancer
  • Roundtable discussion and Q + A: clinical implications of new data
    Eric Van Cutsem, Yelena Janjigian

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings